The Longevity Investment Boom: A trillion-dollar shift

The longevity economy is currently valued at $8 trillion, with end-of-decade growth projections ranging from $12 trillion to an astonishing $27 trillion by 2030.

To put that in perspective, the entire global pharmaceutical market is worth roughly $1.7 trillion, meaning the longevity economy has potential to be many times larger than the value of all pharma companies combined.

This shift is being driven by shifts in demographics, capital, regulation, which build on a quiet century of scientific work - that is now reaching the point where it can be applied to actual patients.

What follows is the story of how this shift happened, why it is accelerating, and why those positioning at the vanguard now will shape the very future of medicine.

A century of quiet work

Serious scientific work on ageing began over a hundred years ago, in laboratories almost no one paid attention to.

In 1903, the biologist Élie Metchnikoff coined the term gerontology, proposing that ageing could be studied as any other biological process. Three decades later, Clive McCay at Cornell showed that rats on a calorie-restricted diet lived significantly longer than those fed normally, the first rigorous demonstration that healthy lifespan could be extended in a mammal. In 1961, Leonard Hayflick discovered that human cells divide a finite number of times before they stop, a limit now named after him. Through the 1990s and 2000s, the cellular machinery of ageing came into focus: telomeres, mitochondrial dysfunction, sirtuins, the mTOR pathway, cellular senescence.

Then in 2013, the biologist Carlos López-Otín co-authored a paper in Cell titled "The Hallmarks of Ageing", proposing that ageing was the result of nine identifiable, measurable and modulatable biological processes.

Genomic instability. Telomere attrition. Epigenetic alterations. Loss of proteostasis. Deregulated nutrient sensing. Mitochondrial dysfunction. Cellular senescence. Stem cell exhaustion. Altered intercellular communication.

The paper became a foundational reference. As López-Otín and colleagues noted in their 2023 follow-up, close to 300,000 articles on ageing have been published in the decade since, as many as in the entire preceding century. 

It gave the field a shared framework and vocabulary, and for the first time, scientists working on different aspects of ageing could see they were all working on the same problem.

The moment ageing became a clinical target

In 2013, Dr. Nir Barzilai, Director of the Institute for Geroscience at Albert Einstein College of Medicine, received a grant from the National Institutes of Health to develop the trial design. The grant was modest by biotech standards. What he proposed to do with it was not.

Rather than testing a drug against disease, Barzilai wanted to test one against ageing itself. He proposed using metformin, an inexpensive diabetes medication, to see whether it could delay a cluster of ageing-related conditions: cardiovascular disease, cancer, cognitive decline and all-cause mortality. He called the trial TAME, for Targeting Ageing with Metformin.

In 2015, Barzilai and a coalition of academics walked into a meeting with the United States Food and Drug Administration, seeking acceptance of a trial design that treated diseases of ageing as a single composite endpoint. To many people's surprise, the regulator agreed.

TAME itself has been delayed for over a decade by funding constraints, and at the time of writing, has yet to begin. Yet the regulatory work has continued. The US government's Advanced Research Projects Agency for Health is now funding parallel initiatives to identify the biomarkers of ageing, while other TAME-style trials are reportedly in preparation.

Whether metformin delivers dramatic results is not the point. What matters is that for the first time, a major regulator accepted a trial structure that treats ageing as a clinical target. Before that moment, no pharmaceutical company could develop a drug for ageing, because no regulatory pathway existed to approve it. After it, there was.

Why ageing begins to matter more

The world faces a growing problem our healthcare system was not built to handle.

Global life expectancy has risen by roughly thirty years over the last century. In most high-income countries, people now live well into their late seventies and beyond. By 2030, one in six people globally will be over sixty, and the population aged sixty and over is projected to reach 2.1 billion by 2050.

But the years gained are not all healthy years.

A 2024 study published in JAMA Network Open found that the global gap between lifespan and healthspan, meaning the number of years a person lives in good health, has now reached 9.6 years on average. In the United States it is 12.4 years. The gap has widened by 13 per cent in two decades.

In plain terms: people are living longer, but spending more of those extra years in decline

This is happening at the moment when the largest, wealthiest generation in history is ageing. Baby boomers own most of the world's housing stock, hold most of its private wealth, and are now growing old. The generation that has spent its life refusing limits accepted by previous generations, is now asking - with serious financial resources behind the question - whether age-related decline is really inevitable?

A parallel demographic shift compounds this. People are having children later. The average age of first-time mothers across the OECD has risen by three years since 2000, from 26.4 to 29.5. Older parents need to remain healthy for longer to raise their children, to be at their graduations, to know their grandchildren. Healthspan is no longer abstract. For a sixty-year-old with a fifteen-year-old child, it becomes a daily question.

These demographics, scientific advances and regulatory shifts unite to create conditions for a major market to form.

The turning point

In January 2022, Altos Labs emerged from stealth. It launched with $3 billion in initial funding, making it the best-funded biotechnology start-up in history.

Its investors included Jeff Bezos, Yuri Milner, and ARCH Venture Partners. Its scientific advisors included Shinya Yamanaka, the Japanese Nobel laureate whose work on cellular reprogramming had defined the previous decade of stem cell research. Its mission was to programme cells back to a younger, more resilient state.

In effect, to reverse the molecular clock of ageing. 

Altos was not the first longevity company. But it represented the moment the field tipped from scientific curiosity to investable thesis. Once Bezos and Milner committed $3 billion, many family offices, sovereign wealth funds and pharmaceutical companies took notice.

Within months, Retro Biosciences had launched with $180 million seeded by Sam Altman, and is now raising a $1 billion Series A at a five-billion-dollar valuation, while longevity investment more than doubled to $8.5 billion in 2024, up from $3.8 billion in 2023.

The investor profile has shifted from speculative venture capital to sovereign wealth funds, family offices, strategic corporate investors and major pharmaceutical companies entering the space.

The access problem

For investors, the challenge is access.

Longevity science is complex and the field is moving fast. Separating genuine breakthroughs from hype requires deep domain expertise, regulatory understanding, and direct relationships with the researchers and clinicians actually translating the science.

For researchers and clinicians, the challenge runs in reverse.

They have promising science, but need access to funding, regulatory pathways, clinical infrastructure and routes to market. They need to be in rooms with the people who can actually move their work from laboratory to patient.

The gap between these two worlds is the single biggest bottleneck in the longevity field today. The science is ready. The capital is ready. The clinicians are ready. They are simply not in the same rooms often enough.

Closing this gap is a deliberate goal of Next Generation Medicine.

Where clinical meets capital

Next Generation Medicine is the platform where these worlds meet.

Where investors hear directly from the researchers translating science into clinical practice. Where clinicians discover the technologies entering their field. Where founders connect with the capital and the partners they need to scale.

Across four days at Atlantis The Royal in Dubai, sixty senior clinicians, scientists and innovators present and debate the breakthroughs defining the field. Our broad agenda, created by global leaders in the field, encompasses longevity therapeutics, regenerative medicine, precision diagnostics as well as the economics of a new healthcare model. 

For sponsors and partners, the congress offers a rare commercial opportunity.

The chance to align with the institutions and individuals defining the future of healthcare. The chance to put innovations in front of a curated audience of decision-makers. Visibility across digital platforms, event materials and communications reaching thousands of highly targeted, engaged professionals. 

Why now is the moment

Think about how artificial intelligence got to where it is today.

A long, quiet build through the 2010s. A handful of breakthrough moments, most visibly the arrival of large language models in late 2022. Then a flood of capital, and within eighteen months, AI was everywhere. Those who placed their bets in 2017 and 2018 are the ones defining the field today, while those who waited are now playing catch up.

Longevity medicine is currently sitting where AI was in 2017. The science has progressed and regulatory pathways are opening, while he cultural conversation has shifted, and capital is starting to move at a serious scale.

Early movers are now quietly building the brand equity, the clinical relationships and the market position that will compound over the next decade.

The window to be early is still open. It will not stay open for long.

And in comparison with AI, longevity may actually become the more important investment thesis. AI will reshape productivity, and that is significant. But longevity medicine reshapes what it means to be alive. The total market for AI is the global services economy. The total market for longevity is every human being alive today.

What comes next

The longevity investment boom represents a structural shift in how we understand health, ageing and the purpose of medicine itself.

The goal is no longer simply to treat disease as it arises. The goal is to prevent it. To optimise function across the lifespan. To help people live not just longer, but better.

This represents the future that Next Generation Medicine 2026 is built around.

Places are limited in a congress bringing together sixty world-leading experts and delegates from over twenty countries.

Join us. 7 to 10 November 2026. Atlantis The Royal, Dubai.

Get tickets.
Become a partner.